The panel is designed to simultaneously detect 21 respiratory pathogens including several atypical bacteria in a single closed-tube system.

As part of the deal, Affymetrix will sell Luminex's Magpix, Luminex 200, and Flexmap 3D multiplexed assay platforms in specified geographies.

The firm plans to officially launch and introduce the PCR-based platform and herpes assay over the next several weeks.

The firm saw a profitable quarter driven by increases in assay sales and royalty revenues, despite a $7.1 million legal settlement with Enzo Life Sciences.

The firm expects to receive both FDA clearance and CE-IVD marking for the system and assay by the end of 2015 and has more assays in development.

Luminex will pay Enzo Biochem $7.1 million to settle a lawsuit alleging infringement of patents for oligonucleotides and solid supports for fixed nucleic acids.

The company is preparing for the fourth quarter launch of its Aries sample-to-answer system and assays, as well as its NxTag Respiratory Pathogen Panel.

Infectious disease assays accounted for 64 percent of total assay sales in the quarter.

The company aims to seek US and European approval later this year.

Luminex said its technology will enhance the processing speed and capacity of Assurex's tests.


An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.